$NVAX
Novavax, Inc.
PRICE
$7.21 ▼-7.898%
Last Close
VOLUME
5,557,737
DAY RANGE
7.11 - 7.79
52 WEEK
5.61 - 76.77
Join Discuss about NVAX with like-minded investors
@ivtrades-Chris #ivtrades
$NVAX - Bearish flow noted in Novavax (13.70 -3.54) with 12,121 puts trading, or 4x expected. The Put/Call Ratio is 1.85, while ATM IV is up nearly 5 points on the day. Earnings are expected on 02/27. The JAN 2023 $10.00 Puts and DEC 16th 12.50 Puts are active.
113 Replies 11 👍 7 🔥
@soheil.n #StockTraders.NET
totally missed...forgot to add to watchlist > @singletary said: $nvax killer
58 Replies 10 👍 6 🔥
Key Metrics
Market Cap
677.49 M
Beta
0
Avg. Volume
6.85 M
Shares Outstanding
86.31 M
Yield
0%
Public Float
0
Next Earnings Date
2023-08-07
Next Dividend Date
Company Information
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
CEO: Stanley Erck
Website: novavax.com
HQ: 21 Firstfield Rd Gaithersburg, 20878-1757 Maryland
Related News